Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Lori

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
AIDS (London, England)|January 26, 2005
Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytesLuca Lova, Antonella Groff, Elisabetta Ravot, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2008
HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individualsSandra A Calarota, Andrea Foli, Renato Maserati, et al.
Nanoscale|September 23, 2021
Effective SARS-CoV-2 antiviral activity of hyperbranched polylysine nanopolymersLuigi Stagi, Davide De Forni, Luca Malfatti, et al.
DNA and Cell Biology|February 18, 2004
T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infectionMax W Richardson, Andrij E Sverstiuk, Peter Silvera, et al.
Current HIV Research|May 17, 2007
Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAARTRenato Maserati, Andrea Foli, Lina Tomasoni, et al.
AIDS (London, England)|December 13, 2002
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized studyFelipe García, Montserrat Plana, Mireia Arnedo, et al.
Plos One|October 25, 2012
VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeuticsFranco Lori, Davide De Forni, Elly Katabira, et al.
AIDS (London, England)|January 1, 2005
Control of viral rebound through therapeutic immunization with DermaVirJulianna Lisziewicz, Jeffrey Trocio, Jianqing Xu, et al.
Plos One|May 17, 2012
Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individualsJulianna Lisziewicz, Nyasha Bakare, Sandra A Calarota, et al.
Viruses|October 28, 2023
Reply to Taylor et al. Comment on "Manna et al. SARS-CoV-2 Inactivation in Aerosol by Means of Radiated Microwaves. <i>Viruses</i> 2023, <i>15</i>, 1443"Antonio Manna, Davide De Forni, Marco Bartocci, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
AIDS (London, England)|January 26, 2005
Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytesLuca Lova, Antonella Groff, Elisabetta Ravot, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2008
HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individualsSandra A Calarota, Andrea Foli, Renato Maserati, et al.
Nanoscale|September 23, 2021
Effective SARS-CoV-2 antiviral activity of hyperbranched polylysine nanopolymersLuigi Stagi, Davide De Forni, Luca Malfatti, et al.
DNA and Cell Biology|February 18, 2004
T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infectionMax W Richardson, Andrij E Sverstiuk, Peter Silvera, et al.
Current HIV Research|May 17, 2007
Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAARTRenato Maserati, Andrea Foli, Lina Tomasoni, et al.
AIDS (London, England)|December 13, 2002
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized studyFelipe García, Montserrat Plana, Mireia Arnedo, et al.
Plos One|October 25, 2012
VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeuticsFranco Lori, Davide De Forni, Elly Katabira, et al.
AIDS (London, England)|January 1, 2005
Control of viral rebound through therapeutic immunization with DermaVirJulianna Lisziewicz, Jeffrey Trocio, Jianqing Xu, et al.
Plos One|May 17, 2012
Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individualsJulianna Lisziewicz, Nyasha Bakare, Sandra A Calarota, et al.
Viruses|October 28, 2023
Reply to Taylor et al. Comment on "Manna et al. SARS-CoV-2 Inactivation in Aerosol by Means of Radiated Microwaves. <i>Viruses</i> 2023, <i>15</i>, 1443"Antonio Manna, Davide De Forni, Marco Bartocci, et al.
Pageof 5